Donor lymphocyte infusion (DLI) has been used successfully to induce remissions in relapse of acute myeloid leukaemia (AML) after bone marrow transplantation (BMT), but molecular eradication of leukaemia has rarely been documented. A patient with AML-M4Eo relapsed after HLA-identical sibling BMT in first complete remission (CR). Cytogenetic and molecular genetic investigations confirmed inv(16) and CBF␤/MYH11 fusion characteristic of M4Eo. A second remission was obtained with chemotherapy. Full donor chimerism was demonstrated by fluorescence in situ hybridisation. However, molecular evidence of minimal residual disease still persisted, and donor lymphocyte infusion (DLI) was administered. This resulted in molecular eradication, and the patient remained in clinical and molecular remission 16 months from DLI. Our observations showed that, for AML relapse after BMT, molecular leukaemia eradication could be achieved by DLI so that, in cases where genetic markers are available, molecular monitoring should be performed to assess the efficacy of treatment. Keywords: acute myeloid leukaemia; donor lymphocyte infusion; molecular remission Effective consolidation of remission by either additional chemotherapy or myeloablative treatment with stem cell rescue (bone marrow transplantation, BMT) is a key factor leading to long-term survival in patients with acute myeloid leukaemia (AML). In patients receiving allogeneic BMT, a graft-versus-leukaemia (GVL) effect contributes significantly to disease eradication.
AML relapses, 2 with little data to show molecular eradication of leukaemia. 5 We report the serial cytogenetic and molecular genetic findings in a patient with AML-M4Eo who relapsed after BMT, and achieved a second remission with chemotherapy consolidated with DLI.
Materials and methods

Case report
A 43-year-old woman presented in 1994 with acute myelomonocytic leukaemia with eosinophilia (AML-M4Eo), which was confirmed by the presence of inv(16)(p13;q22) cytogenetically. A complete remission (CR) was obtained with idarubicin (12 mg/m 2 /day ϫ 3 days) and cytosine arabinoside (ara-C) (100 mg/m 2 /day ϫ 7 days). This was followed by two consolidation courses with the same drugs. BMT was performed at CR1 with an HLA-identical brother as donor. Busulphan (16 mg/kg) and cyclophosphamide (120 mg/kg) were used for conditioning. Cyclosporin and methotrexate were used as graft-versus-host disease (GVHD) prophylaxis. There was no acute or chronic GVHD. She relapsed 2 years later, and a second CR was obtained with chemotherapy (ara-C 1 g/m 2 /day ϫ 4 days, mitoxantrone 12 mg/m 2 /day ϫ 3 days; followed by one course of ara-C 6 g/m 2 /day ϫ 2 days). To further consolidate the remission, DLI was given (total lymphocyte dose of 0.49 ϫ 10 8 cells/kg from a single leukapheresis session), without GVHD prophylaxis. There was no evidence of GVHD, and the patient has remained in remission for 16 months since the DLI.
Karyotyping, fluorescence in situ hybridization (FISH) and molecular studies
Cytogenetic study was performed on overnight fluorodeoxyuridine synchronized culture of marrow cells and karyotyped according to ISCN (1995) . FISH analysis was performed with a chromosome X centromeric probe (Oncor, Gaithersburg, MD, USA) as previously described. 6 Reverse transcription polymerase chain reaction (RT-PCR) for the CBF␤/MYH11 transcript characteristic of inv(16) was performed with two pairs of nested CBF␤ ((outer) 5Ј-GCA GGC AAG GTA TAT TTT GAA GG/(inner) 5Ј-GAC TGG ATG GTA TGG GCT GT) and MYH11 ((outer) 5Ј-CTC TTC TCC TCA TTC TGC TC/(inner) 5Ј-TGA GCG CCT GCA TGT TGA CT) primers. Reaction conditions were as previously described. 7 Integrity of RNA was shown by amplification of the ␤2-microglobulin transcript.
Results
The molecular and cytogenetic results are summarized in Table 1 . At presentation, inv(16)(p13;q22) was present. RT-PCR yielded a 282 bp PCR product (Figure 1 ), consistent with fusion of CBF␤ at nt 495 to MYH11 at nt 1921. 8 Before BMT, although the marrow was in morphologic remission, minimal residual leukaemia was still detectable by PCR. At post-BMT relapse, the same clone was detected by RT-PCR. After completion of chemotherapy, the marrow was in morphologic remission and was reconstituted by donor cells only, as demonstrated by FISH (Table 1) . Nevertheless, despite morphological and FISH evidence of CR, the leukaemic clone was still detectable molecularly. However, 1 month after DLI, the leukaemic clone had become undetectable by RT-PCR. The latest RT-PCR result in her peripheral blood was still negative. 
Discussion
The cytogenetic abnormality inv(16)(p13q22) is associated with acute myelomonocytic leukaemia with abnormal eosinophils, and fusion of the CBF␤ and MYH11 genes. Molecular remission as assessed by serial PCR for the chimeric CBF␤/MYH11 is highly predictive of prolonged remission. [8] [9] [10] For AML patients relapsing after BMT the therapeutic options include re-induction chemotherapy, second BMT, and augmentation of the GVL effect by DLI. Intensive reinduction chemotherapy only results in short remissions.
11
A second BMT is associated with significant morbidity and mortality. 12 On the other hand, DLI has been effective against a wide range of haematological malignancies relapsing post BMT. [2] [3] [4] However, DLI might be associated with potentially life-threatening complications including severe GVHD and marrow aplasia. 2, 13 Two prerequisites appear necessary for successful DLI. Firstly, it is more successful in minimal residual leukaemia than in gross haematological relapse, [2] [3] [4] as an initial cytoreduction might reduce the relapse clone to a level that can be effectively handled by GVL.
14 Secondly, the preservation of donor chimerism is important to avoid bone marrow aplasia post DLI. 13 These conditions were met in our case. At post-BMT relapse, cytoreduction with chemotherapy successfully reduced the leukaemic clone to a level undetectable by conventional FISH analysis, but molecular remission was not attained. On the other hand, after DLI molecular eradication of the leukaemic clone was achieved, probably due to a putative GVL effect. While the clinical efficacy of DLI in AML has been shown in some cases, molecular markers for studying minimal leukaemia are seldom available and thus molecular remission has rarely been reported. 5 The presence of a molecular marker in our case has therefore allowed us to document the efficacy of DLI in achieving molecular remission of AML. Finally, molecular monitoring has been successful in guiding pre-emptive DLI in preventing relapse of CML after BMT. 5 Our observations show that in AML where a molecular marker is present, a similar strategy might also be adopted.
